李泽钜：长江生命科技(00775.HK)去年溢利下跌因受利息影响

阿斯达克财经05-23

长江生命科技(00775.HK) 举行股东周年大会，主席李泽钜表示，去年溢利下降乃由于财务成本增加1.59亿元，远超除税及扣除财务成本前溢利增长2,310万元。若利率维持于2022年水平，2023年股东应占溢利约1.81亿元，上升约37%。简单来说，溢利下跌全因利息，营运方面其实正在增长。黑色素瘤疫苗研发方面，副总裁及科学总监杜健明表示，公司旗下处于最后期研究阶段的癌症疫苗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2437272512?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20240523111750793_s.jpg","is_english":false,"pubTime":"2024-05-23 11:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2437272512","market":"sh","top_or_hot":-1,"title":"李泽钜：长江生命科技(00775.HK)去年溢利下跌因受利息影响","media":"阿斯达克财经","content":"<div>\n<p>长江生命科技(00775.HK) 举行股东周年大会，主席李泽钜表示，去年溢利下降乃由于财务成本增加1.59亿元， 远超除税及扣除财务成本前溢利增长2,310万元。若利率维持于2022年水平，2023年股东应占溢利约1.81亿元，上升约37%。简单来说，溢利下跌全因利息，营运方面其实正在增长。黑色素瘤疫苗研发方面，副总裁及科学总监杜健明表示，公司旗下处于最后期研究阶段的癌症疫苗...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1351558/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>李泽钜：长江生命科技(00775.HK)去年溢利下跌因受利息影响</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n李泽钜：长江生命科技(00775.HK)去年溢利下跌因受利息影响\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-23 11:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1351558/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>长江生命科技(00775.HK) 举行股东周年大会，主席李泽钜表示，去年溢利下降乃由于财务成本增加1.59亿元， 远超除税及扣除财务成本前溢利增长2,310万元。若利率维持于2022年水平，2023年股东应占溢利约1.81亿元，上升约37%。简单来说，溢利下跌全因利息，营运方面其实正在增长。黑色素瘤疫苗研发方面，副总裁及科学总监杜健明表示，公司旗下处于最后期研究阶段的癌症疫苗...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1351558/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1521","symbol_name":"挪威政府全球养老基金持仓","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1351558/latest-news/AAFN","article_id":"2437272512","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20240523111750793_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437272512","pubTimestamp":1716433800,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"长江生命科技举行股东周年大会，主席李泽钜表示，去年溢利下降乃由于财务成本增加1.59亿元， 远超除税及扣除财务成本前溢利增长2,310万元。若利率维持于2022年水平，2023年股东应占溢利约1.81亿元，上升约37%。简单来说，溢利下跌全因利息，营运方面其实正在增长。杜健明提到，长江生命科技于2022年透过认购Pharus股份开拓癌症诊断领域。Pharus目前正为肺癌患者进行临床试验，以开发专门针对肺癌的microRNA检测技术。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1521":"挪威政府全球养老基金持仓","BK1500":"做空集合股","BK1161":"生物科技","00001":"长和","LU1048588211.SGD":"Blackrock Asian Dragon A2 SGD-H","BK1569":"长和系","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE0032431581.USD":"PINEBRIDGE GREATER CHINA EQUITY \"A\" (USD) ACC","LU0072462343.USD":"贝莱德亚洲巨龙基金","BK1230":"工业集团企业","BK1601":"香港本地股","00775":"长江生命科技"},"translate_title":"Li Zeju: CK Life Sciences (00775. HK) 's profit fell last year due to the impact of interest","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00001":1,"00775":1},"content_text":"长江生命科技(00775.HK) 举行股东周年大会，主席李泽钜表示，去年溢利下降乃由于财务成本增加1.59亿元， 远超除税及扣除财务成本前溢利增长2,310万元。若利率维持于2022年水平，2023年股东应占溢利约1.81亿元，上升约37%。简单来说，溢利下跌全因利息，营运方面其实正在增长。黑色素瘤疫苗研发方面，副总裁及科学总监杜健明表示，公司旗下处于最后期研究阶段的癌症疫苗seviprotimut-L，可为第IIB及IIC期黑色素瘤患者于进行根除性手术后作安全而有效的辅助性疗法。纵使包括新冠疫情等因素窒碍疫苗生产，公司正设法克服挑战，以开展关键性的第三阶段临床试验。杜健明提到，长江生命科技于2022年透过认购Pharus股份开拓癌症诊断领域。Pharus目前正为肺癌患者进行临床试验，以开发专门针对肺癌的microRNA检测技术。于今年1月，Pharus与美国一家大型癌症中心City of Hope签订一项全球独家协议，授权使用其专有生物标记以助开发及商品化用于胰管腺癌早期检测的液体活检。另外，副总裁及行政总监余英才称，长江生命科技与晶泰科技致力开发先进的癌症疫苗研发平台，几种先进的AI算法已经成功开发，并用于设计首批潜在的胜肽癌症疫苗，目前正在透过体外和体内实验进行筛选，以验证其免疫原性和抗肿瘤效能方面的表现。(ha/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437272512"}